2-CMDO

Discontinued Product

2-CMDO (Cat. No. 0782) has been withdrawn from sale for commercial reasons.
Cat.No. 0782 - 2-CMDO | C19H19ClN2O.C4H4O4 | CAS No. 24140-98-5
Description: D2-like antagonist; displays some D4 selectivity
Chemical Name: 2-Chloro-11-(4-methylpiperazino)dibenz(Z)[b,f]oxepin maleate
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for 2-CMDO

2-CMDO is a dopamine D2-like receptor antagonist that displays some selectivity for D4 receptors (Ki values are 0.54 and 2.5 nM for D4 and D2 receptors respectively).

Technical Data for 2-CMDO

M. Wt 442.9
Formula C19H19ClN2O.C4H4O4
Storage Store at RT
CAS Number 24140-98-5
PubChem ID 71296946
InChI Key OOHVXDUNWCMZCI-WLHGVMLRSA-N
Smiles [H]OC(=O)\C=C\C(=O)O[H].CN1CCN(CC1)C1=CC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for 2-CMDO

References are publications that support the biological activity of the product.

Phillips et al (1994) Binding of 5H-dibenzo[b,e][1,4]diazepine and chiral 5H-dibenzo[a,d]cycloheptane analogues of cloz. to DA and serotonin receptors. J.Med.Chem. 37 2686 PMID: 8064797

Phillips et al (1995) Binding of 5H-dibenzo[a,d]cycloheptane and dibenz[b,f]oxapin analogues of cloz. to DA and serotonin receptors. J.Med.Chem. 38 708 PMID: 7861418

Zawilska et al (2003) L-745,870 suppresses the nighttime serotonin N-acetyltransferase activity in chick retina: in vivo evidence for agonist activity at D4-DA receptors. J.Neural Transm. 110 219 PMID: 12658371

View Related Products by Target

View Related Products by Product Action

View all Non-selective Dopamine Antagonists

Keywords: 2-CMDO, 2-CMDO supplier, D2-like, antagonists, Displays, D4, selectivity, Dopamine, Non-Selective, Receptors, dopaminergic, 2-Chloro-11-(4-methylpiperazino)dibenz[b,f]oxepin, maleate, Non-selective, 0782, Tocris Bioscience

Citations for 2-CMDO

Citations are publications that use Tocris products.

Currently there are no citations for 2-CMDO.

Reviews for 2-CMDO

There are currently no reviews for this product. Be the first to review 2-CMDO and earn rewards!

Have you used 2-CMDO?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Dopamine Receptors

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.